Accutar Biotechnology Announces FDA Approval of IND Application for Phase 1 Clinical Trial of AC0176 for Prostate Cancer

Accutar Biotechnology Inc. a biotechnology company focused on drug discovery using the power of artificial intelligence (AI), today announced that it is resistant to metastatic caster . Announced that the US Food and Drug Administration (FDA) has approved a new drug clinical trial start notification (IND) for AC0176 to treat patients with prostate cancer (mCRPC). AC0176 is an orally administrable chimeric degrading molecule designed to target androgen receptor (AR) degradation with high potency, selectivity, and wide range of mutation coverage. AR is a hormone-controlled transcription factor whose activation plays a vital role in the development and progression of prostate cancer. Accutar is expected to begin enrollment in Phase 1 clinical trials for AC0176 in the first quarter of 2022. Dr. Jie Fan, CEO of Accutar Biotechnology, Inc., said: "We have just entered clinical trials for AC0682, but the IND approval of AC0176 reveals that our AI platform can potentially differentiate clinical candidates, especially complex compounds such as chimeric degradative molecules. It is important once again to prove that we can support and move forward quickly, and the IND approval of AC0176 is the current standard of care for this patient population, second-generation non-steroidal AR. It is crucial in providing new therapeutic candidates based on a different mechanism of action from antagonists. We look forward to the clinical benefits that AC0176 may bring to patients with prostate cancer. I am. " This Phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AC0176 treatment in patients with mCRPC. About AC0176 AC0176 is an orally administrable investigational drug as a chimeric androgen receptor (AR) -degrading molecule and is a candidate for the treatment of prostate cancer. AC0176 has demonstrated potent and selective AR protein degradation, good pharmacological properties, and promising antitumor activity in animal models while covering a wide range of AR mutations in preclinical studies. About Accutar Biotechnology Accutar is a clinical biotechnology company focused on drug discovery using the power of AI, as well as its application to drug discovery and development of clinically differentiated medicines. Be transformative. For the patient.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!